156 completed, 19 unknown, 8 recruiting, 6 active not recruiting. 200 Phase 3, 30 Phase 2.
Follow Lacrimal Apparatus Diseases: new trials by email Literature Review of Lacrimal Apparatus Diseases trials Research Report on Lacrimal Apparatus Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers Deucravacitinib - Systemic Lupus Erythematosus, Sjögren's Disease | Phase 3 | Not yet recruiting | Bristol-Myers Squibb | 2300 | 2026-12-31 | 2026-09-03 |
| Phase III Study of Topical Fibrinogen-Depleted Human Platelet Lysate Compared to Placebo for Moderate to Severe Dry Eye CAM-101, Vehicle Control - Dry Eye Disease, Dry Eye | Phase 3 | Not yet recruiting | Cambium Bio Limited | 475 | 2026-10-01 | 2026-06-12 |
| Phase III Study of OT202 in Treating Moderate to Severe Dry Eye OT202 conc 1%, Placebo - Dry Eye | Phase 3 | Recruiting | Ocumension Therapeutics (Suzhou) Co., Ltd | 842 | 2026-08-25 | 2026-10-15 |
| Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden VAY736, Placebo - Sjögren´s Disease | Phase 3 | Recruiting | Novartis Pharmaceuticals | 570 | 2026-07-16 | 2026-10-13 |
| A Clinical Study Evaluating Licaminlimab for Dry Eye Disease Artificial Tear Run-in, licaminlimab, Vehicle of licaminlimab - Dry Eye Disease (DED) | Phase 2 / Phase 3 | Active not recruiting | Oculis | 160 | 2026-04-16 | 2026-10-27 |
| Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease Telitacicept, Placebo - Primary Sjogren's Disease | Phase 3 | Recruiting | Vor Biopharma | 250 | 2026-02-26 | 2026-10-19 |
| 3% Diquafosol Ophthalmic Solution for Active Moderate-to-Severe Vernal Keratoconjunctivitis 3% Diquafosol ophthalmic solution and 0.1% Cyclosporin A cationic ophthalmic emulsion, 0.1% Cyclosporin A cationic ophthalmic emulsion - Vernal Keratoconjunctivitis | Phase 3 | Recruiting | The University of Hong Kong | 94 | 2026-02-09 | 2026-04-30 |
| A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease ABBV-444, REFRESH OPTIVE UD - Dry Eye Disease | Phase 3 | Completed | AbbVie | 261 | 2025-12-15 | 2026-09-17 |
| A Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination in Subjects With Dry Eye Disease Lifitegrast/perfluorohexyloctane (PFHO) - Dry Eye Disease | Phase 3 | Withdrawn | Bausch & Lomb Incorporated | 2025-12-01 | 2025-12-10 | |
| Clinical Trial for the Evaluation of Safety and Efficacy of Drop 0.4% Multidose mosturizing solution DROP 0.4%, Multidose mosturizing solution Avizor Eye Drops 0.2% Preserved - Eye Dryness | Phase 3 | Not yet recruiting | Avizor SA | 79 | 2025-07-01 | 2025-07-09 |
| A Study to Evaluate the Efficacy and Safety of Treatment With CsA-PG Ophthalmic Gel in Dry Eye Patients CsA-PG Ophthalmic Gel, CsA Ophthalmic Gel - Dry Eye Disease | Phase 3 | Not yet recruiting | Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | 396 | 2025-05-20 | 2025-04-29 |
| A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) Dazodalibep - Sjögren's Syndrome | Phase 3 | Recruiting | Amgen | 844 | 2025-02-25 | 2026-04-28 |
| A Study to Evaluate 0.003% AR-15512 Safety and Drop Attributes 0.003% AR-15512 ophthalmic solution, Artificial tears - Dry Eye Disease | Phase 3 | Completed | Alcon Research | 55 | 2025-01-15 | 2026-03-17 |
| Efficacy and Safety of SJP-0132 Eye Drops in Chinese Patients With Dry Eye Disease SJP-0132, Placebo - Dry Eye | Phase 3 | Completed | Senju Pharmaceutical Science & Technology (Beijing) Co., Ltd. | 427 | 2024-12-30 | 2025-11-26 |
| Nipocalimab in Moderate to Severe Sjogren's Disease Nipocalimab, Placebo, Standard of care treatment - Sjogrens Syndrome | Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 655 | 2024-12-04 | 2026-09-25 |
| A Study Designed to Evaluate Tear Production 0.003% AR-15512 ophthalmic solution - Dry Eye Disease | Phase 3 | Completed | Alcon Research | 81 | 2024-10-15 | 2026-02-10 |
| A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease 0.003% AR-15512 ophthalmic solution, Artificial Tears - Dry Eye Disease | Phase 3 | Completed | Alcon Research | 80 | 2024-10-08 | 2026-03-27 |
| A Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution - Dry Eye Disease | Phase 3 | Completed | Aldeyra Therapeutics, Inc. | 116 | 2024-06-24 | 2025-12-22 |
| A Phase 3 Study to Evaluate AZR-MD-001 in Patients with Abnormal Meibomian Gland Function and Dry Eye Disease (DED) AZR-MD-001, Vehicle - Dry Eye Disease | Phase 3 | Unknown | Azura Ophthalmics | 500 | 2024-05-28 | 2024-09-27 |
| To Evaluate the Efficacy and Safety of HUC3-053 in Patients With Dry Eye Syndrome HA 0.3%, Hyalein Mini Eye Drops - Dry Eye Syndromes | Phase 3 | Completed | Huons Co., Ltd. | 297 | 2024-05-20 | 2026-03-05 |
Showing 20 of 200. Sign in to see all of them.
Dry Eye Syndromes (176) · Sjogren's Syndrome (26) · Keratoconjunctivitis Sicca (23) · Conjunctival Diseases (5) · Corneal Diseases (5) · Autoimmune Diseases (3) · Lacrimal Duct Obstruction (3) · Xerostomia (3) · Arthritis, Rheumatoid (2) · Cataract (2) · Fatigue (2) · Hyperemia (2) · Keratoconjunctivitis (2) · Lupus Erythematosus, Systemic (2)
Eye Diseases (199) · Immune System Diseases (28) · Conjunctival Diseases (27) · Arthritis (26) · Conjunctivitis (26) · Joint Diseases (26) · Mouth Diseases (26) · Musculoskeletal Diseases (26) · Rheumatic Diseases (26) · Salivary Gland Diseases (26) · Skin and Connective Tissue Diseases (26) · Stomatognathic Diseases (26) · Connective Tissue Diseases (25) · Arthritis, Rheumatoid (24)
Cyclosporins (10) · Ophthalmic Solutions (7) · Cyclosporine (6) · lifitegrast (6) · Lubricant Eye Drops (4) · Nasal Sprays (4) · ianalumab (4) · rebamipide (4) · Docosahexaenoic Acids (3) · Loteprednol Etabonate (3) · Tacrolimus (3) · Varenicline (3) · thymosin beta(4) (3) · Carboxymethylcellulose Sodium (2) · Fatty Acids, Omega-3 (2)
Allergan (11) · Aldeyra Therapeutics, Inc. (7) · Bausch & Lomb Incorporated (6) · Merck Sharp & Dohme LLC (6) · Alcon Research (5) · Huons Co., Ltd. (5) · Mimetogen Pharmaceuticals USA, Inc. (5) · Novartis Pharmaceuticals (4) · Shire (4) · Aerie Pharmaceuticals (3) · Amgen (3) · HanAll BioPharma Co., Ltd. (3) · Kala Pharmaceuticals, Inc. (3) · Kissei Pharmaceutical Co., Ltd. (3) · Novaliq GmbH (3)
United States (107) · South Korea (25) · China (16) · Spain (15) · France (14) · Japan (14) · Canada (12) · Italy (12) · Germany (11) · Mexico (11) · United Kingdom (11) · Australia (10) · Brazil (9) · Poland (9) · Taiwan (9)
Eiji Murakami (3) · Gail Torkildsen, MD (3) · Garth Cumberlidge, PhD (3) · Roger Vogel, MD (3) · Sonja Kroesser, PhD (3) · Amy Schaberg, BSN (2) · Flavio Mantelli, MD (2) · Johnson Varughese (2)
PMID 36729473, PMID 15502479, PMID 26365210, PMID 28079022, PMID 39564145, PMID 41038456, PMID 42470519, PMID 11879137, PMID 14508260, PMID 15090417, PMID 15604871, PMID 16371776, PMID 17043506, PMID 17324465, PMID 18848318, PMID 19958541, PMID 20735287, PMID 21078194, PMID 21479340, PMID 21740369, PMID 22435675, PMID 22615787, PMID 22914501, PMID 22972393, PMID 23229693, PMID 24289915, PMID 24727841, PMID 25473263, PMID 25686388, PMID 25708147, PMID 26065354, PMID 26689380, PMID 26785742, PMID 26890669, PMID 27051257, PMID 27055211, PMID 27366013, PMID 27390310, PMID 27445067, PMID 27645318, PMID 28736342, PMID 28736344, PMID 28777385, PMID 28956287, PMID 29018685, PMID 29432648, PMID 29545413, PMID 29652551, PMID 29883769, PMID 29970389
2023 (2), 2016 (1), 2025 (1), R34EY017626 (1), U10EY011751 (1), U10EY022879 (1), U10EY022881 (1)